血管炎、CA19-9及神经周围侵犯对胰腺导管腺癌治疗反应和手术结局的差异化预测作用
本研究纳入46例临界可切除胰腺导管腺癌患者,比较新辅助化疗(NAC)与NAC联合立体定向体部放疗(SBRT)后行根治性切除术的结局。血管炎与更差的总生存相关(14.5 vs 28.3个月;HR 12.96;95%CI 3.55-47.28;P<.001),NAC-SBRT未增加血管炎发生率。神经周围侵犯和高基线CA19-9(>191 U/mL)为不良生存预测因素。
要点
- 血管炎患者中位总生存14.5个月 vs 无血管炎者28.3个月,HR 12.96(95%CI 3.55-47.28;P<.001)。
- NAC-SBRT组血管炎发生率与NAC组无显著差异(OR 1.64;95%CI 0.40-8.43;P=.52)。
- 神经周围侵犯和高基线CA19-9(>191 U/mL)为不良生存预测因素。
核心结论
- 血管炎预测胰腺导管腺癌患者较差的生存结局。
- 与NAC相比,NAC-SBRT未增加血管炎的发生率。
- 神经周围侵犯和CA19-9仍是强有力的预后因素。
研究设计与样本
- 收集2014年至2019年间接受NAC或NAC-SBRT后行根治性切除术的临界可切除胰腺导管腺癌(临床T3-T4N0-1)患者的临床数据。
- 对手术标本中的血管结构进行组织学评估以判断血管炎。
- 采用RNA测序评估差异基因表达并生成富集图,采用多变量分析评估患者特征与肿瘤学结局的关系。
- 共46例患者符合纳入标准(NAC组12例,NAC-SBRT组34例),中位随访20.1个月。
主要发现
- 所有患者均接受根治性切除术,91.3%达到R0切除。
- NAC组与NAC-SBRT组在失败模式、总生存或进展无生存方面无显著差异。
- 血管炎患者中位总生存14.5个月 vs 无血管炎者28.3个月(HR 12.96;95%CI 3.55-47.28;P<.001)。
- 炎症与手术并发症或病理缓解之间无显著相关性。
- 新辅助治疗对血管炎的发生无显著影响(NAC-SBRT的OR 1.64;95%CI 0.40-8.43;P=.52)。
关键数值与推荐
- 不良生存预测因素包括神经周围侵犯和高基线CA19-9(>191 U/mL)。
- 对CA19-9新辅助治疗反应强烈(>20%下降)的患者富集了免疫反应、趋化作用以及细胞毒性T细胞和自然杀伤细胞增殖。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Curative intent treatment of pancreatic adenocarcinoma (PDAC) relies on surgical resection. Modern treatment protocols focus on optimizing neoadjuvant therapy to increase resectability and improve oncologic outcomes. To elucidate differences in outcomes, we investigated the relationship between neoadjuvant chemotherapy (NAC), either with or without stereotactic body radiation therapy (SBRT), and vascular inflammation, surgical outcomes, and the resultant transcriptomic changes. METHODS AND MATERIALS: Clinical data were collected from patients with borderline resectable PDAC (clinical T3-T4N0-1) who underwent NAC or NAC-SBRT followed by curative intent resection between 2014 and 2019. Vascular structures on surgical specimens were histologically evaluated for vasculitis. RNA sequencing was used to evaluate differential gene expression and to generate enrichment maps. Multivariate analysis was used to analyze the relationship between patient characteristics and oncological outcome. RESULTS: In total, 46 patients met inclusion criteria (n = 12 NAC, n = 34 NAC-SBRT) with a median follow-up of 20.1 months. All patients underwent curative resection, with 91.3% achieving R0. There was no significant difference in patterns of failure, overall survival, or progression-free survival between NAC and NAC-SBRT groups. Patients with vasculitis had a lower median overall survival compared with those without (14.5 vs 28.3 months; hazard ratio, 12.96; 95% confidence interval, 3.55-47.28; P < .001). There was no significant correlation between inflammation and surgical complications or pathologic response. Neoadjuvant therapy did not have a significant effect on development of vasculitis (odds radio, 1.64 for NAC-SBRT; 95% confidence interval, 0.40-8.43; P = .52). Predictors of poor survival included perineural invasion and high baseline carbohydrate antigen 19-9 (CA19-9) (>191 U/mL). Patients with robust CA19-9 (>20% decrease) responses to neoadjuvant therapy had enrichment in immune response, chemotaxis, and cytotoxic T-cell and natural killer-cell proliferation. CONCLUSIONS: Vasculitis predicts for poor survival outcomes in patients with PDAC; NAC-SBRT did not increase the rate of vasculitis compared with NAC. Perineural invasion and CA19-9 remain strong prognosticators. Understanding and optimizing immune interactions remain a crucial hurdle in achieving response in pancreatic cancer.
引用
- Piper M, Ross RB, Hu J, et al. Vasculitis, CA19-9, and Perineural Invasion Differentially Predict Response and Surgical Outcome in Pancreatic Ductal Adenocarcinoma. Int J Radiat Oncol Biol Phys. 2023. PMID: 36599398. doi:10.1016/j.ijrobp.2022.12.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。